STOCK TITAN

Cabaletta Bio, Inc. - CABA STOCK NEWS

Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.

Cabaletta Bio, Inc. (symbol: CABA) is a clinical-stage biotechnology company dedicated to the discovery and development of engineered T cell therapies for patients suffering from B cell-mediated autoimmune diseases. Utilizing its proprietary Chimeric AutoAntibody Receptor (CAAR) and Chimeric Antigen Receptor T cells for autoimmunity (CARTA) technologies, Cabaletta aims to provide targeted, effective, and potentially curative treatments.

The company's flagship product candidate, DSG3-CAART, is in Phase I clinical trials for treating mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Other promising candidates include MuSK-CAART for myasthenia gravis and FVIII-CAART for a subset of patients with hemophilia A. Cabaletta is also actively developing DSG3/1-CAART for mucocutaneous pemphigus vulgaris, with several products in various stages of preclinical and discovery phases.

In recent developments, Cabaletta Bio received approval from the U.S. FDA for its Investigational New Drug (IND) application for CABA-201, a fully human CD19-CAR T cell investigational therapy for generalized myasthenia gravis (gMG). This expands their portfolio into neurology, complementing prior clearances for lupus, myositis, and systemic sclerosis. The upcoming Phase 1/2 clinical trial for CABA-201 aims to test its efficacy in treating gMG patients, potentially offering a groundbreaking one-time dose treatment.

Furthermore, Cabaletta has secured multiple Fast Track Designations from the FDA for CABA-201 in conditions like dermatomyositis and systemic sclerosis, facilitating expedited development and review. These designations highlight the critical unmet needs in these patient populations and amplify Cabaletta’s commitment to pioneering advanced therapies.

Based in Philadelphia, PA, Cabaletta Bio continues to advance its innovative pipeline, guided by robust scientific research and strategic collaborations. The company is well-positioned financially, with adequate resources to fund its operations into the first half of 2026. Cabaletta's mission is to harness the power of engineered T cells to unlock transformative therapies, offering patients durable, drug-free remissions and improved quality of life.

Rhea-AI Summary
Cabaletta Bio's third IND application for CABA-201 has been cleared by the FDA for a Phase 1/2 study in patients with systemic sclerosis (SSc). The company plans to initiate a clinical trial with two parallel cohorts. Three-month clinical data from initial patients treated with CABA-201 in lupus and/or myositis trials are on track to be reported by H1 2024. CABA-201 has the potential to slow or halt the progression of SSc, providing an important treatment option for patients. SSc affects approximately 88,000 patients in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
-
Rhea-AI Summary
Cabaletta Bio, Inc. to participate in two investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
conferences
-
Rhea-AI Summary
Cabaletta Bio, Inc. to participate in four investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
Rhea-AI Summary
Cabaletta Bio expands partnership with WuXi ATU for manufacturing of CABA-201 cell therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.68%
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags

FAQ

What is the current stock price of Cabaletta Bio (CABA)?

The current stock price of Cabaletta Bio (CABA) is $3.985 as of November 4, 2024.

What is the market cap of Cabaletta Bio (CABA)?

The market cap of Cabaletta Bio (CABA) is approximately 188.6M.

What is Cabaletta Bio's primary focus?

Cabaletta Bio specializes in developing engineered T cell therapies for B cell-mediated autoimmune diseases.

What are some of Cabaletta Bio's key product candidates?

Key candidates include DSG3-CAART for mucosal pemphigus vulgaris, MuSK-CAART for myasthenia gravis, and CABA-201 for generalized myasthenia gravis.

What is CABA-201 and why is it significant?

CABA-201 is an investigational CD19-CAR T cell therapy designed to offer a one-time dose treatment for autoimmune diseases, recently cleared for trials by the FDA.

Has Cabaletta Bio received any regulatory designations?

Yes, Cabaletta Bio has received multiple Fast Track Designations from the FDA for CABA-201 in treating conditions like dermatomyositis and systemic sclerosis.

Where is Cabaletta Bio headquartered?

Cabaletta Bio is headquartered in Philadelphia, PA.

What is the current financial condition of Cabaletta Bio?

Cabaletta Bio has sufficient funds to support its operating plan into the first half of 2026.

What stages are Cabaletta Bio's clinical trials in?

Cabaletta Bio's lead candidate DSG3-CAART is in Phase I trials, while CABA-201 is preparing for Phase 1/2 trials across multiple autoimmune conditions.

What makes Cabaletta Bio's technology proprietary?

Cabaletta Bio utilizes proprietary CAAR and CARTA technologies to specifically target and eliminate disease-causing B cells while sparing healthy cells.

What recent achievements has Cabaletta Bio made?

Cabaletta Bio recently received FDA approval for multiple IND applications and Fast Track Designations, underscoring its innovative pipeline's potential.

How does Cabaletta Bio aim to impact patient care?

Cabaletta Bio aims to provide deep and durable treatments, potentially offering drug-free remissions and significantly improving patient quality of life.

Cabaletta Bio, Inc.

Nasdaq:CABA

CABA Rankings

CABA Stock Data

188.56M
48.85M
3.1%
105.81%
7.74%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
PHILADELPHIA